Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
Status:
Unknown status
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential
hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on
treating mild-moderate essential hypertension patients.